The global market for artificial intelligence in pathology is witnessing a significant surge, driven by advances in digital imaging, image analysis and machine learning. The market is projected to witness a compound annual growth rate (CAGR) of 17.62% between 2025 and 2035. By 2035, it is anticipated to reach a valuation of approximately USD 0.66 billion, indicating strong investment and advancements in AI technologies. In 2024, the market stood at USD 0.11 billion, marking the early phase of AI integration in pathology. The rising adoption of AI solutions, driven by the growing need for precise and efficient diagnostic tools, remains a key factor propelling market growth.
Market Overview
The AI in pathology market merges digital pathology with advanced analytics, computer vision and deep learning techniques. At its core, the market is being shaped by the transition from traditional glass-slide microscopy toward whole-slide imaging (WSI), cloud-based digital workflow platforms, and AI-powered diagnostic and decision‐support tools. The increasing global burden of chronic diseases—particularly cancer—combined with a shortage of trained pathologists, rising demand for precision medicine and the push to automate routine workflow tasks are all accelerating adoption. Furthermore, regulatory acceptance of digital pathology and AI-enabled diagnostics is slowly strengthening, making it feasible for larger scale commercialization.
Across components, the software and services segments dominate as the enabling layers for analytics and AI algorithms, while hardware such as image scanners and servers provide the infrastructural backbone. With segmentation by technology, computer vision–based image analysis and machine learning models drive the largest share, given their ability to identify and quantify tissue features, cells and biomarkers from digital slides. In terms of applications, diagnostic and clinical workflows account for large uptake, while drug discovery and research use‐cases are gaining rapidly thanks to AI’s ability to process high-throughput histology and image datasets. End users span hospitals, diagnostic laboratories, research institutes, and pharmaceutical/biotech organisations.
Request To Free Sample of This Strategic Report ➤➤➤ https://www.marketresearchfuture.com/sample_request/26816
Key Market Segments
In terms of components, the software segment holds the largest share — an unsurprising outcome given that AI models and analytics are central to the value proposition. For example, the software share was around 51 % in 2024 according to one report. Hardware and services form the remainder, with service contracts, training and integration adding value. By technology, machine learning leads (around 35.8 % share in 2024) followed by deep learning or convolutional neural networks (CNNs) and image-analysis frameworks. Among applications, image analysis tops the list (about 36.4 % share in 2024), followed by functions such as data management, analytics and clinical decision support systems (CDSS).
By end-use, hospitals remain the largest adopters because they have high slide volumes and strong incentives to improve turnaround time and accuracy; diagnostic labs and research institutes are also gaining traction as AI-platform vendors extend into those segments. Geographically, North America claimed the largest share in 2024 (~40.5 %), while Asia-Pacific is forecast to grow fastest over the coming years given rising healthcare infrastructure, unmet pathology resources and increasing chronic disease burden.
Industry Latest News
Recent developments illustrate how AI in pathology is moving from research to deployment. For example, a major partnership was announced by University of Pittsburgh (Pitt) and Leidos, worth USD 10 million over five years, aimed at leveraging AI to improve cancer and heart-disease diagnostics, with a particular focus on underserved communities. That initiative emphasises the push to expand pathology AI outside major urban centres and into broader healthcare systems. Meanwhile, in the UK, researchers at University of Cambridge trained an AI tool on more than 4,000 images from multiple hospitals to speed up diagnosis of coeliac disease, achieving performance comparable to human pathologists but at far faster speed.
These stories underline two important trends: (1) AI tools are now sufficiently mature to challenge traditional workflows for less complex diagnoses, and (2) healthcare systems are actively investing in digitisation and AI-enabled pathology services to address workforce shortages and backlog issues. At the same time, regulatory, interoperability and standardisation challenges remain. For instance, the EMPAIA International initiative (European multi-stakeholder) is working on vendor-neutral interfaces and standards to facilitate the clinical integration of AI pathology tools—offering lessons on how the ecosystem is evolving beyond hype into practical deployment.
Buy Now Premium Research Report ➤➤➤ https://www.marketresearchfuture.com/checkout?step=2&report_id=26816¤cy=one_user-USD
Key Companies
Several established and emerging players are shaping the AI in pathology market. Leading firms include
- Intellisite LLC
- PathAI
- Kheiron Medical
- Ibex Medical Analytics
- Corista,
- Contextvision AB
- Leica Biosystems
- Proscia
- PhilipsAI
- Indica Labs
- Sectra
- Inspirata
- Visiopharm
- Arterys
These companies engage in strategic initiatives such as AI algorithm development, partnerships with scanner vendors, software platform integrations, and clinical validation studies. For example, Owkin has collaborated with major pharmaceutical firms on spatial-omics and pathology AI projects. The competitive landscape is also being shaped by venture-backed start-ups offering niche AI tools for cytology, immunohistochemistry quantification, or companion diagnostics. As such, the market is highly dynamic with consolidation expected as regulators clear more AI diagnostic tools and hospitals scale digital pathology adoption.
Market Drivers
Several key drivers underpin the expansion of AI in pathology. First, the growing prevalence of cancer and other chronic diseases worldwide increases demand for pathology services, thereby creating a need for faster, more accurate diagnostics and higher throughput. AI systems help reduce diagnostic errors, support early detection and enable more consistent interpretations across pathologists. Second, there is a global shortage of qualified pathologists, especially in emerging markets and smaller hospitals; AI-powered tools can automate routine image analysis tasks (such as cell segmentation, counting and biomarker quantification) thereby freeing up human experts for more complex cases.
Third, the shift toward precision medicine—which requires integrating imaging, histology, genomics and multi-omics data—favors AI platforms that can synthesise diverse data types and generate actionable insights. Fourth, technological improvements such as whole-slide scanners, digital archiving, cloud infrastructure and interoperability standards are lowering barriers to deployment of AI in pathology labs. Fifth, growing funding and partnerships (including public-private initiatives) accelerate AI tool development and clinical validation, fostering a virtuous cycle of adoption. Finally, workflow pressure in hospitals and labs (e.g., backlog of cases, need for remote review and telepathology) has increased the urgency of AI-based pathology solutions to improve efficiency and reduce turnaround times.
Browse In-depth Market Research Report ➤➤➤ https://www.marketresearchfuture.com/reports/ai-in-pathology-market-26816
Regional Insights
Regionally, North America leads adoption of AI in pathology thanks to advanced healthcare infrastructures, high digitisation rates in pathology labs, significant R&D investment and mature regulatory frameworks. The United States is a major driver with early deployment of digital pathology and AI tools. Europe is the second-largest region and is growing steadily; factors such as supportive government initiatives, growing investments in healthcare digitisation and strong pathologist networks help adoption.
➤➤ Explore MRFR’s Related Ongoing Coverage In Healthcare Domain:
Iron Deficiency Anemia Treatment Market
Carboprost Tromethamine Market
